Background. Overconsumption of dietary sugars, fructose in particular, is linked to cardiovascular risk factors such as type 2 diabetes, obesity, dyslipidemia and nonalcoholic fatty liver disease. However, clinical studies have to date not clarified whether these adverse cardiometabolic effects are induced directly by dietary sugars, or whether they are secondary to weight gain.
Objectives. To assess the effects of fructose (75 g day À1 ), served with their habitual diet over 12 weeks, on liver fat content and other cardiometabolic risk factors in a large cohort (n = 71) of abdominally obese men.
Methods. We analysed changes in body composition, dietary intake, an extensive panel of cardiometabolic risk markers, hepatic de novo lipogenesis (DNL), liver fat content and postprandial lipid responses after a standardized oral fat tolerance test (OFTT).
Results. Fructose consumption had modest adverse effects on cardiometabolic risk factors. However, fructose consumption significantly increased liver fat content and hepatic DNL and decreased b-hydroxybutyrate (a measure of b-oxidation). The individual changes in liver fat were highly variable in subjects matched for the same level of weight change. The increase in liver fat content was significantly more pronounced than the weight gain. The increase in DNL correlated positively with triglyceride area under the curve responses after an OFTT.
Conclusion. Our data demonstrated adverse effects of moderate fructose consumption for 12 weeks on multiple cardiometabolic risk factors in particular on liver fat content despite only relative low increases in weight and waist circumference. Our study also indicates that there are remarkable individual differences in susceptibility to visceral adiposity/liver fat after real-world daily consump
Introduction
Cardiovascular disease (CVD) continues to be the leading cause of death in the world. Numerous risk factors for CVD have been identified, including a number of nutritional factors. Dietary sugars have come under scrutiny because of epidemiologic studies suggesting a possible link between sugarsweetened beverages and CVD risk factors such as type 2 diabetes, obesity, hypertension and dyslipidemia [1] [2] [3] [4] [5] [6] [7] [8] . In addition, overconsumption of dietary sugars has been linked to nonalcoholic fatty liver disease (NAFLD).
How do dietary sugars promote fatty liver? Increased hepatic lipids in NAFLD may result from increases in dietary fat, esterification of plasma free fatty acids and/or hepatic de novo lipogenesis (DNL) [9] [10] [11] [12] . Fructose has been shown to promote hepatic lipogenesis by stimulating SREBP-1c and ChREBP, two master transcriptional regulators of DNL [3, [13] [14] [15] [16] . Because this stimulation does not require insulin, fructose can promote hepatic lipid accumulation even in the setting of insulin resistance. Fructose also leads to ATP depletion and suppression of hepatic mitochondrial fatty acid oxidation, thus favouring liver fat storage [13, 17, 18] . Excess consumption of fructose may also operate indirectly by delivering extra energy leading to weight gain and ectopic fat depots including liver fat content [1, 6, 8, 19] .
Most mechanistic studies elucidating the deleterious effects of fructose have been performed in rodents [20] . However, because DNL in rodents differs from that in humans [20] , it is not clear how relevant these findings are for humans. Recent meta-analyses have identified several limitations in clinical studies investigating the adverse metabolic effects of fructose (such as small sample sizes, short intervention periods, variable doses of fructose intake and studies in healthy lean subjects with low baseline liver fat content) [21] [22] [23] . These limitations may explain the discrepant conclusions of the trials studying the effect of fructose consumption on liver fat content [20] . However, it appears that a hypercaloric fructose diet increases liver fat content in obese subjects. For example, Ma et al. reported that real-world doses of sugarsweetened beverages in the Framingham imaging cohort (n = 2634) were associated with increased risk of fatty liver disease, particularly in overweight and obese individuals [24] . However, it still remains unclear whether this is due to direct metabolic effects of fructose or merely a result of increased energy intake.
Support for direct metabolic effects of fructose comes from studies showing that dietary sugars, in particular fructose, increase DNL in humans [11, 19, [25] [26] [27] [28] [29] . However, liver fat quantifications were not performed in any of these studies, and the effects of fructose on liver fat content therefore remain unclear. Recently, Schwartz et al. reported that a short-term high-fructose weight-maintaining diet (25% of energy content for 9 days) was associated with increases in both DNL and liver fat in eight healthy men [30] . This result strengthens the notion that excess fructose intake has direct adverse effects on liver lipid metabolism.
The aim of this study was to assess the effects of fructose (75 g day À1 for 12 weeks served as a lemonade together with habitual ad libitum diet) on liver fat content measured by magnetic resonance examinations in a large cohort of abdominally obese men with and without other cardiometabolic risk factors. We also analysed changes in body composition, dietary intake, an extensive panel of cardiometabolic risk markers, hepatic DNL as well as responses of postprandial lipids to a standardized oral fat tolerance test (OFTT).
Subjects and methods

Study subjects
A total of 82 obese healthy men were recruited to the study (Clinical Trials NCT01445730) at four centres: in Helsinki, Finland; Naples, Italy; Quebec, Canada; and Gothenburg, Sweden. Subjects were recruited via newspaper advertisements. Inclusion criteria were as follows: men with large waist circumference (>96 cm), body mass index (BMI) between 27 and 40 kg m
À2
, stable weight (AE3 kg) over the preceding 3 months, low-density lipoprotein (LDL) cholesterol <4.5 mmol L À1 and serum triglycerides (TG) <5.5 mmol L À1 . Exclusion criteria were as follows: age <20 years or >65 years, BMI or lipid levels outside the inclusion ranges, smoking, alcohol consumption over 2 doses day À1 (i.e. 20 g pure alcohol), type 2 diabetes, cardiovascular disease, hormonal therapy, hepatic and renal diseases, gastroenterological, thyroid or haematological abnormalities, and any chronic disease requiring medication except for controlled hypertension. None of the subjects used any medication or hormones known to influence lipoprotein metabolism.
The study design was approved by the local ethics committees, and each subject gave written informed consent before participation in the study. All studies were performed in accordance with the Declaration of Helsinki for clinical trials.
Fructose intervention
Subjects underwent a 12-week fructose intervention period, during which they consumed 75 g of fructose daily (303 kcal), administered as three 330-mL bottles. The carbonated beverages were prepared as 7.6% (w/w) solutions and flavoured with lemon aroma (produced for this study by Nokian Panimo Oy, Finland). Subjects were instructed to consume the beverages together with the three main daily meals whilst continuing their habitual ad libitum diet during the intervention. The fructose-sweetened beverage was well tolerated. Of the 82 subjects, two subjects discontinued the intervention study: one developed a skin rash which was considered as possible allergic reaction to flavouring. The rash disappeared after the discontinuation. The other subject discontinued the study in response to his dentist's advice. In addition, the data from magnetic resonance examinations at baseline or after the fructose intervention were not sufficient from nine subjects for technical reasons to allow the analyses of different fat depots. Thus, 71 subjects completed the full study protocol.
The subjects' weight and height were measured in the study centre after an overnight fast and barefoot with underwear. The waist circumference was recorded at the midpoint between the lower rib margin and the iliac crest. Three consecutive readings were taken, and the mean was recorded. A qualified nutritionist gave detailed verbal and written instructions for filling in the food records. The compliance was assessed based on weekly reporting of adherence to fructose beverages on a compliance sheet where the subjects indicated the number of beverages missed during the week. The dietician contacted (i.e. face-to-face visits, phone calls or email messages) the subjects once per week to monitor weight and compliance. Each subject kept a 3-day food record (2 work days and 1 day off) before the fructose intervention period and again within 2 weeks before completing the intervention period. Participants were not required to weigh foods but were asked to measure the volume of foods consumed with household measurements or to indicate the weight of the products. After completing the food records, participants met with the local dietitians to review the food records for completeness. Energy and nutrient intake were calculated by linking the food intake information with local food composition databases. The 3-day energy and nutrient values were averaged to obtain mean intakes for each subject.
Study design
The protocol included four separate study visits before the fructose intervention period: (i) oral glucose tolerance test (OGTT), (ii) OFTT, (iii) heparin test and (iv) magnetic resonance examinations. These visits were repeated within 2 weeks before completing the 12-week fructose intervention period.
A 75 g OGTT was performed in the morning after an overnight fast. The subjects consumed 75 g of glucose, and blood samples were taken after 5, 10, 30, 60, 90, 120, 180 and 240 min.
On a separate day, a standardized OFTT was performed in the morning after an overnight fast. The subjects received a fat-rich meal (927 kcal) consisting of bread, butter, cheese, ham, boiled eggs, fresh red pepper, low-fat (1%) milk, orange juice and tea or coffee (63 g carbohydrate, 56 g fat and 40 g protein). Blood samples were drawn before and at 2, 3, 4, 6 and 8 h after the meal. During the test, only water was allowed ad libitum and the subjects remained physically inactive. The participants abstained from alcohol and physical exercise for 2 days before each examination.
In a subgroup of 56 subjects, DNL was analysed before and at 4 and 8 h after the meal during the OFTT. A blood sample was drawn as a background sample in the week before the OFTT. Subjects received 2 g kg À1 body weight deuterated water 2 H 2 O (Larodan Fine Chemicals, Sweden) which was consumed in two servings together with evening meal on the day before the OFTT [31] .
The heparin test was performed after an overnight fast, and the subjects received a bolus of 75 IU kg À1 heparin i.v. The lipoprotein lipase and hepatic lipase masses and activities were measured from the blood samples collected 12 min after the heparin injection. determine liver fat content [32, 33] . Magnetic resonance imaging was used to determine subcutaneous abdominal and intra-abdominal fat expressed as volumes [34] . A standardized protocol was used at all centres, and all analyses of the imaging results were performed by one person (AH). Subjects were advised to fast for 4 h before imaging.
Biochemical analyses
Lipoprotein fractions [chylomicrons (Sf > 400), large very low-density lipoprotein (VLDL 1 ) particles (Sf 60-400) and smaller VLDL 2 particles (Sf 20-60)] from blood samples drawn before and during the OFTT were separated by density gradient ultracentrifugation. As all fractions contain both apolipoprotein (apo)B48 and apoB100 particles, they were further analysed using SDS-PAGE [35] . TG and cholesterol concentrations in total plasma and in lipoprotein fractions were analysed by automated enzymatic methods using the Konelab 60i analyser (Thermo Fisher Scientific, Finland). Fasting and postprandial apoB48 levels in total plasma were measured by ELISA (Shibayagi Co., Shibukawa, Japan). Fasting and postprandial concentrations of glucose (hexokinase method, Roche Diagnostic Gluco-quant, Germany) and insulin (electrochemiluminescence with Roche sandwich immunoassay on a Cobas autoanalyser) were measured after the fat-rich meal. Plasma levels of apoC-III, fibroblast growth factor 21 (FGF-21) and adiponectin were measured by ELISA (R&D Systems, Minneapolis, USA), and 3-hydroxybutyrate concentrations were measured by an enzymatic method with b-hydroxybutyrate FS kit (DiaSys Diagnostic Systems, Holzheim, Germany) on a Konelab 60i analyser (Thermo Fisher Scientific, Finland).
Statistical methods
Statistical analyses were performed using R version 3.1.1 for Windows (https://www.r-project. org/), Stata (version 13.0, Stata Corporation, TX, USA) and GraphPad Prism version 7 (http:// www.graphpad.com/scientific-software/prism/). For all variables, P values were calculated using the Wilcoxon signed-rank test or the Mann-Whitney U-test. As many clinical variables could not be assumed to be normally distributed, these nonparametric tests were used. Correlation coefficients and their corresponding P values were calculated using Spearman 0 s rank test. A P value <0.05 was considered statistically significant. Stepwise regression analysis was performed using the 'step' function in R. Bidirectional elimination was used in the selection of variables. The underreporting of energy intake was evaluated by determining the ratio of reported energy intake to estimated basal metabolic rate (BMR). The BMR was estimated from the age-and gender-specific equations proposed by Schofield [36] . A cut-off value of 0.9 was used to identify extreme underreports of energy intake [37] . All analysis involving energy intake was subjected to a sensitivity analysis in which we excluded underreporters, but because results were virtually unchanged, only the results including all subjects are presented. To elucidate the mechanisms for the responses of liver fat to the diet intervention, we divided the subjects into three groups according to their change in liver fat after fructose. Group 1 (n = 22) had reduced liver fat content (from 7.2 AE 1.4% at baseline to 5.5 AE 1.3% after fructose feeding), Group 2 (n = 20) had no or minimal liver fat change, and Group 3 (n = 29) gained liver fat (from 8.5 AE 1.2% to 11.2 AE 1.2%).
Results
Study cohort characteristics at baseline
Baseline data of the 71 men who completed the 12-week fructose intervention are shown in Table 1 . The subjects showed a wide range of BMI (25.6-38.3 kg m À2 ), liver fat (0.3-24.8%) and other adiposity indices. BMI correlated modestly with visceral fat (r = 0.28, P = 0.02) but not with liver fat content. Visceral fat (r = 0.35, P = 0.004) but not waist circumference or subcutaneous fat correlated significantly with liver fat. The HOMA index averaged 2.8 AE 1.8% with a large range (0-8.5%) and correlated modestly with liver fat (r = 0.31, P = 0.008), baseline DNL (r = 0.36, P = 0.008) and FGF-21 (r = 0.33, P = 0.004) but not with weight or visceral fat. Baseline DNL also correlated with fasting insulin (r = 0.40, P = 0.003) but not with fasting glucose nor with liver fat content.
Of the 71 participants, 27 had elevated fasting TG levels (>1.7 mmol L À1 ). These men had an overall worse cardiometabolic profile with higher HOMA index, blood glucose, apoC-III, FGF-21, and uric acid and lower adiponectin than subjects with normal fasting TG levels (Table S1 ). However, the two groups had comparable weight and waist circumference (Table S1 ) and did not significantly differ in either liver fat content (6.5 AE 1.0% vs. 6.9 AE 0.9%) or visceral and subcutaneous fat depots (Table S2 ). There was a trend for a higher VAT/SAT ratio in the subjects with elevated TG levels (P = 0.058) ( Table S2) .
Effects of fructose feeding on diet composition
Dietary intake calculated from 3-day food records at baseline and during the fructose intervention period are shown in Table 2 . As expected, the consumption of 75 g of fructose per day caused significant changes in the macronutrient composition. However, because the study subjects adjusted their diets, the increased energy intake during the fructose intervention was small (only 54 kcal) and did not reach statistical significance. The proportion of energy from total carbohydrates was higher, but that of sucrose, protein, total fat and saturated and unsaturated fatty acids was lower during the fructose intervention period. Although the average intake of total fat reduced significantly by 6.6 AE 3.3 g day À1 , there were large variations in the individual changes of saturated fat intake during fructose intervention (from À33.5 to 28.6 g day
À1
). The energy provided by fructose was 2.5 AE 0.2% of the total energy intake at baseline and increased to 14.7 AE 0.3% during the intervention. During the fructose diet, 12.9 AE 0.3% of energy was from added fructose and 1.8 AE 0.1% of energy was from fructose present in the habitual diet. Intake of cholesterol, total fibre and alcohol was not significantly different between baseline and the fructose intervention period ( Table 2) .
Effects of fructose feeding on body composition
Fructose intervention resulted in minor but significant increases in weight (1.1 AE 1.7%) and waist circumference (0.67 AE 2.5%) ( Table 1) . Changes in waist circumference correlated positively with changes in weight (r = 0.53, P < 0.001) and subcutaneous fat area (r = 0.40, P = 0.002) but only modestly with changes in visceral fat (r = 0.29, P = 0.02) and liver fat (r = 0.30, P = 0.01). There was a large variation in individual weight response to the fructose intervention: the majority (n = 37) gained weight (>1 kg), 26 subjects remained weight stable and eight subjects lost weight (>1 kg). There were no significant differences in total energy intake between these three groups during the diet intervention and no correlation between changes of energy intake and body weight (data not shown).
Liver fat content was increased by about 10% after the 12-week fructose intervention (6.7 AE 0.7 vs. 7.3 AE 0.8%, P < 0.01), but no significant changes were seen in visceral or subcutaneous fat depots (Table 1 ). There was a positive correlation between changes in liver fat and weight (r = 0.26, P = 0.03) after fructose feeding (Fig. 1a) . Notably, changes of subcutaneous fat correlated strongly with changes of weight (r = 0.46, P < 0.001) (Fig. 1b) , but no correlation was observed between changes of visceral fat and weight (r = 0.16, NS). Changes of liver fat content correlated also with respective changes of waist circumference (r = 0.30, P = 0.01), subcutaneous fat (r = 0.37, P = 0.002), insulin (r = 0.25, P = 0.04) and HOMA (r = 0.31, P = 0.01). We observed no correlation between the changes of saturated fat intake and liver fat (r = 0.18, P = 0.14).
Next, we performed a multivariate regression analysis of seven selected parameters (changes in subcutaneous fat, FGF-21, apoC-III, saturated fat intake, fructose intake, DNL and total fat intake) to test their explanatory power for changes of liver fat in response to the diet intervention. The whole model explains 27% of the variance (adjusted R-squared), but no individual variable explained more than 5% of the variance alone (Table S3) .
To further elucidate the mechanisms for the responses of liver fat to the diet intervention, we divided the subjects into three groups according to their change in liver fat after fructose. Group 1 (n = 22) had reduced liver fat content (from 7.2 AE 1.4% at baseline to 5.5 AE 1.3% after fructose feeding), Group 2 (n = 20) had no or minimal liver fat change, and Group 3 (n = 29) gained liver fat (from 8.5 AE 1.2% to 11.2 AE 1.2%). Adverse changes of cardiometabolic risk factors were most common in Group 3 (Table 3 and Table S4 ).
Next, we analysed differences in diet that could explain the different responses between Group 1 and Group 3. We showed that subjects who gained most liver fat had slightly lower fructose intake at baseline than subjects who lost liver fat
. In addition, these subjects increased significantly calorie intake (P = 0.03) probably due to less clear reduction in saturated fat intake (Table S5) . However, the actual difference of changes between the two groups showed only a nonsignificant trend towards higher intake of energy and saturated fat after fructose feeding (Table S5) .
To clarify the impact of genetic polymorphisms, we analysed three polymorphisms that are known to modify the liver fat metabolism: PNPLA3, TM6SF2 and MBOAT7. We showed that increased numbers of risk alleles correlated with increased liver fat content before diet intervention (Fig. 2a) . However, there was no difference in the number of risk alleles between Group 1 and Group 3 (Fig. 2b) . Furthermore, there were no differences in liver fat change in response to the diet intervention between individuals with and without risk alleles (Fig. 2c) . Thus, these three polymorphisms did not explain the different responses between Group 1 and Group 3.
Effect of fructose feeding on cardiometabolic risk markers and hepatic lipid metabolism
We next analysed the impact of the diet intervention on postprandial lipid responses. At baseline, plasma TG and apoB48 levels increased at early time points after the fat-rich meal ( Fig. 3 and Table S6 ). Importantly, baseline apoC-III showed strong positive correlations with both baseline TG (Fig. 4a ) and TG AUC (Fig. 4b) . At baseline, both fasting TG and TG AUC (after a fat-rich meal) correlated negatively with plasma adiponectin (r = À0.37 and À0.42, respectively, P < 0.001), but the correlation between TG AUC and liver fat content was only modest (r = 0.30, P = 0.01).
The responses of both plasma total TG and apoB48 levels to the fat-rich meal were higher after fructose feeding (Fig. 3) . Both plasma TG and apoB48 were augmented by fructose feeding for up to 120 min after the high-fat meal. The overall responses of plasma total TG, measured as AUC as well as iAUC were increased after fructose feeding (Table S6) . We did not observe any significant changes in AUCs of TG and apoB48 in chylomicrons, VLDL 1 or VLDL 2 fractions after fructose feeding (Table S6) .
Fructose feeding induced significantly higher systolic blood pressure values (but not heart rate), fasting insulin and HOMA index (Table 1) . Both fasting serum TG levels and apoC-III increased significantly after fructose intervention (Table 1) . Importantly, apoC-III showed strong positive correlations with TG and postprandial TG AUCs after fructose feeding (Fig. 4c,d ). In addition, the apoC-III change after fructose feeding correlated significantly with changes of TG and TG AUCs (Fig. 4e,f) .
Fructose feeding was not associated with significant changes in fasting FFA, FGF-21 or uric acid concentrations (Table 1) , or in glucose or insulin AUCs during an OGTT (data not shown). Notably, we observed a strong correlation between liver fat and FGF-21 values before (Fig. 5a ) and after ( Fig. 5b) fructose feeding.
Fructose feeding resulted in significant increases in DNL in the fasting state (12.3 vs. 16.5% de novo palmitic acid in VLDL 1 , P < 0.01) and also at 4 and 8 h postprandially (data not shown). In contrast, fructose feeding resulted in a significant decrease in fasting levels of b-hydroxybutyrate (P = 0.005), a surrogate marker of hepatic lipid b-oxidation. We further observed an inverse relationship between the changes in DNL and b-hydroxybutyrate in response to fructose intervention (r = À0.42, P = 0.002). Importantly, the increase in DNL correlated positively with the respective change of postprandial TG AUC (r = 0.43, P = 0.001). Thus, the fructose-stimulated DNL may contribute to the increased postprandial TG responses.
We next selected seven variables (changes of apoC-III, DNL, insulin, HOMA, weight, saturated fat intake and total fat intake) and tested their Fig. 2 The different response to the diet intervention is independent from PNPLA3, TM6SF2 and MBOAT7. a) Increased number of risk alleles associates with increased liver fat content before diet intervention. b) No differences in the number of risk alleles between Group 1 and Group 3. Group 1 (n = 22) had reduced liver fat content (from 7.2 AE 1.4% at baseline to 5.5 AE 1.3% after fructose feeding) and Group 3 (n = 29) gained liver fat (from 8.5 AE 1.2% to 11.2 AE 1.2%). c) Individuals without or with risk allele do not have differences in liver fat change in response to the diet intervention. Data are shown as mean value and standard deviation (continuous traits) or as percentage. P value was calculated by linear regression analysis (a), ordinal regression (b) or Mann-Whitney nonparametric test for independent samples (c). Risk alleles: TM6SF2 T; PNPLA3 G; MBOAT7 T. explanatory power for TG AUC change after fructose intervention in a multivariate regression analysis. The whole model explains 73.7% of the variance (adjusted R-squared). Multiple regression analysis identified the apoC-III change as the strongest predictor for the change of TG AUC followed by those of DNL, insulin and HOMA change. Importantly, apoC-III alone explained 59% of the variance, whereas DNL alone explained 16% of the variance in changes in TG AUC (Table S7) .
Discussion
A central finding in this study is that a real-world daily consumption of fructose-sweetened beverages for 12 weeks had significant but modest adverse effects on multiple cardiometabolic risk Fig. 3 Responses of plasma TG and apoB48 after a fat-rich mixed meal before and after fructose feeding. The P-values have been calculated using the Wilcoxon signed-rank test. *P < 0.05. The AUC before versus after for TG (a) and (b) apoB48 are shown. factors. We also report that the fructose consumption significantly increased liver fat content and hepatic DNL and decreased levels of b-hydroxybutyrate (indicating decreased hepatic b-oxidation). Interestingly, the individual changes of liver fat were highly variable in subjects with the same weight change (Fig. 1) . However, the average relative increase in liver fat (10%) was more pronounced than the significant but low relative increases in weight (1.1%) and waist circumference (0.5%). Importantly, the adverse changes of cardiometabolic risk factors seemed to cluster more with the increase in liver fat than with the weight gain.
Our intervention was intended to be hypercaloric, in which the fructose-sweetened beverages were consumed in addition to the habitual diet. The fructose dose (75 g day À1 , corresponding to 13% of the energy intake) was slightly higher than the mean consumption of fructose in the United States (55 g day À1 ) [37] , but comparable to the dose that is habitually consumed by some high risk groups, including adolescents. According to the third National Health and Nutrition Examination Survey (NHANES III), one-fourth of adolescents consume at least 15% of calories from fructose, mainly from sugar-sweetened beverages, grains, fruit and fruit juices [38] . Thus, both the amount of fructose and the way it was served were chosen to mimic a behaviour which is prevalent in Western societies [39] .
Despite our intention to undertake a hypercaloric intervention study, the reported energy intake was not significantly higher after fructose intervention despite the small but significant increase in weight and waist circumference. The fact that fructosesweetened beverages provided an excess of 300 calories but the daily energy intake increased only by an average of 54 calories indicates that the study subjects reduced their energy intake from other food and beverages. Indeed, the subjects reported significantly decreased intake of saturated fat and sucrose during fructose feeding. Recently, it was reported that 10-week consumption of fructose-sweetened beverages was linked to reduced resting energy expenditure [40] . This would further increase weight gain if total energy intake is not reduced accordingly.
Earlier studies have shown that the size and distribution of fat depots varied significantly also according to the saturation of the fat that was consumed [41] . Rosqvist et al. recently tested whether overeating a diet rich in additional polyunsaturated fatty acids (PUFA) would reduce formation of ectopic fat compared with overeating a diet high in saturated fatty acids (SFA) [42] . The results show that the SFA diet induced a significant increase in liver fat relative to the PUFA diet [42] . In our study, the subjects reduced their intake of dietary saturated fat, which may have counteracted the stimulatory effect of fructose intake on the liver fat accumulation. The reduction in saturated fat was more prominent in subject who lost liver fat than in those who gained liver fat.
A critical question is whether the fructose consumption directly increased liver fat content? Enhanced DNL is reported to contribute significantly to the hepatic triacylglycerols in NAFLD [9, 11, 43] . Fructose (and sucrose in sugarsweetened beverages) acutely and chronically promotes hepatic lipogenesis by stimulating SREBP-1c and ChREBP [3, [13] [14] [15] 25] and suppresses mitochondrial fatty acid oxidation [13, 17, 18] . These processes synergistically promote hepatic storage of lipids and secretion of triglyceriderich VLDL particles [3, 16, 26, 27, 30, [44] [45] [46] [47] . Our observation that DNL was increased during fructose feeding for 12 weeks is consistent with earlier shorter studies [26, [47] [48] [49] [50] [51] and compliments the study by Stanhope et al. [45] showing that increased DNL is maintained during chronic intake of high-fructose liquids. In our study, fructose beverages reduced b-hydroxybutyrate (a surrogate marker of hepatic lipid oxidation). Cox et al. recently reported decreased postprandial fat oxidation in overweight/obese subjects who consumed fructose beverages at 25% of energy requirements for 10 weeks as part of energybalanced ad libitum diet [40] . These changes of energy fluxes were not seen in subjects consuming glucose-sweetened beverages at 25% energy requirements [40] . Notably, DNL also increased significantly, but liver fat changes were not quantitated in these studies [40, 45] .
Fructose is absorbed via the portal vein and delivered at much higher concentrations to the liver compared to other tissues [29] . Thus, highfructose consumption forces the liver to adapt its metabolism against liver toxicity. Key pathways that could be altered include the storage of excess lipids in hepatocytes resulting in steatosis, and the packaging of triacylglycerols in VLDL to remove extra lipids from the liver. The fact that increases in DNL correlated with increases in postprandial TG AUC after fructose intervention suggests that there is a direct link between increased hepatic triacylglycerol synthesis and assembly and secretion of VLDL.
Increased fat oxidation is another adaptive mechanism that prevents liver fat accumulation [7] . Our observation of a reduction in b-hydroxybutyrate during fructose feeding indicates reduced ability of the liver to shuttle fatty acids to oxidation and ketone body formation. FGF21 is considered to be a major regulator of body energy metabolism promoting fatty acid oxidation but suppressing DNL [52, 53] . We observed strong correlations between fasting FGF-21 levels and the liver fat content in line with earlier studies [54, 55] and a negative correlation with b-OH butyrate (r = À0.28, P < 0.017). We observed a nonsignificant trend for increase in fasting FGF-21 levels after fructose feeding in these abdominally obese subjects. Fructose has earlier been reported to increase acutely the response of FGF-21 [56] . In this study, FGF-21 increased about 3.4-fold after acute intake of 75 g of fructose, but so far no data exist on the effects of more chronic intake of fructose. The lack of effect on fasting uric acid could be due to the fact that the greatest effects of fructose-containing sugars on uric acid are observed in the postprandial and not the fasting state [57] .
Postprandial dyslipidemia is a key feature of the atherogenic lipid profile in abdominally obese subjects and is exaggerated in those with hypertriglyceridemia. Acute and short term as well as more chronic intake of high fructose promotes elevation of both fasting and postprandial triglyceride levels in healthy subjects as well as in those with the metabolic syndrome [12, 45, 47, [58] [59] [60] [61] [62] . The data from meta-analyses suggest that these effects on postprandial lipids are induced by both hypercaloric and isocaloric diets [6, 63, 64] . We performed here thorough analyses of triglycerides, apoB48 and apoB100 in serum and different triglyceride-rich lipoprotein fractions to clarify the responses to fructose feeding. We showed that fructose feeding aggravated the increases in both total triglycerides and apoB48 at early time points after a fat-rich meal. However, the differences in total responses of plasma triglycerides and apoB48 AUC after the fructose feeding remained marginal.
Interestingly, we observed a significant rise of apoC-III during fructose feeding in line with recent results by Stanhope et al. [65] . These data are consistent with the possibility that fructose, like glucose, stimulates the expression of apoC-III via ChREBP. We also showed that apoC-III was a strong predictor for postprandial serum TG AUC, both before and after fructose feeding, supporting a role for apoC-III in the clearance of triglyceride-rich lipoproteins [66] .
Our study has several strengths. First, the study group was larger than in any previous mechanistic study using magnetic resonance examinations and stable isotopes to elucidate the adverse effects of fructose on cardiometabolic risk factors. Secondly, the study subjects were genotyped for three key risk alleles for fatty liver development to determine whether they played a role in liver fat responses to fructose. Thirdly, the duration of the study was longer than in earlier acute or short-term mechanistic studies. Fourthly, the amount of fructose was similar to the habitual consumption in the USA and Middle East. An important limitation is that we do not have a control group to specifically disentangle the metabolic effect(s) of weight gain versus fructose. Additional potential weaknesses are that fructose served in beverages may not induce the same metabolic responses as when fructose is ingested as a part of sucrose or in natural compounds; pure fructose may be absorbed less efficiently than sucrose [39] . We cannot confirm that the study subjects really consumed the daily recommended dose of fructose as our compliance assessment was indirect and did not include a measure of blood fructose concentration. Overall the reported compliance was good when recognizing all caveats. Both poor adherence to fructose intake and less absorption of fructose would result in less robust metabolic effects of fructose consumption than actually were seen in our study.
Conclusion
Our data demonstrate that the adverse cardiometabolic effects of fructose consumption over a 12-week period were significant but modest. However, these detrimental cardiometabolic effects may be exacerbated over a longer period time as occurs in the real life. Thus, our results should be interpreted in the context of chronic overconsumption of sugar-sweetened beverages containing fructose amongst heavy consumers who are common across the globe. Our study also indicates that there are remarkable individual differences in susceptibility to visceral adiposity/liver fat deposition and that such differences play a role in modulating the health hazard associated with chronic consumption of fructose-containing beverages.
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